stockrow
Saturday 7 November 2026
Export DCOY’s income statement to Excel — free account
Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
- Revenue
- −84.6%
- EPS
- +94.5%
- Free cash flow
- −212.5%
Quarter to June 2026, against a year earlier
1.13
0.01
+0.89%
Follow DCOY
Alert me
Decoy Therapeutics Inc (DCOY) P/E ratio
Decoy Therapeutics Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| KALA KALA BIO, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| AFMDQ Affimed N.V. compare | n/m |
| DCOY Decoy Therapeutics Inc | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)